EMD Serono, Inc. Announces Expansion with Research Site in Cambridge, Massachusetts
- Supports US Drug Discovery Activities in Neurodegenerative Diseases-
"This research expansion further supports EMD Serono's commitment to develop and deliver innovative therapies for patients in our areas of focus," said
"EMD Serono's continued expansion in
In 2008, EMD Serono announced a planned expansion of its
EMD Serono completed the first Phase III trial of an oral multiple sclerosis drug, cladribine, which is targeted for registration filing later this year. With these additional capabilities the company plans to focus research and development efforts towards Parkinson's disease, and other neurodegenerative diseases.
About EMD Serono, Inc.
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt,
The company has strong market positions in neurodegenerative diseases, with Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R) (somatropin (rDNA origin) for injection) and Serostim(R) (somatropin (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alfa for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alfa injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 1000 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of
For more information, please visit www.emdserono.com
SOURCE EMD Serono, Inc.
More by this Source
EMD Serono Enters into Research Agreement with Pfizer and Broad Institute
Apr 01, 2014, 07:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.